BeyondSpring Inc. (BYSI) CEO Lan Huang on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 09/10/21
BeyondSpring Inc. (BYSI) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 09/10/21
BeyondSpring Announces Second Quarter 2021 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 09/10/21
BeyondSpring Announces Three Poster Presentations About its Chemotherapy-Induced Neutropenia Prevention Program at the European Society for Medical Oncology 2021 CongressGlobeNewsWire • 09/09/21
BeyondSpring Announces Late-Breaking Oral Presentation of Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination Versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for MediGlobeNewsWire • 08/31/21
BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater ChinaGlobeNewsWire • 08/26/21
A small biopharma stock soars 198% after the company says it will seek FDA approval following a successful cancer-drug trialBusiness Insider • 08/04/21
BeyondSpring stock more than triples after lung cancer treatment meets endpoints in Phase 3 trialMarket Watch • 08/04/21
BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild TypeGlobeNewsWire • 08/04/21
BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan DelaneyGlobeNewsWire • 07/14/21